Applied Clinical Trials
Applied Clinical Trials magazine is an internationally recognized, peer-reviewed publication that focuses on the management of clinical trials. It highlights the collaboration between pharmaceutical developers and the medical researchers who conduct rigorous tests on new medications, all within a tightly regulated environment.
Outlet metrics
Global
#826940
United States
#342052
Health/Biotechnology and Pharmaceuticals
#328
Articles
-
3 days ago |
appliedclinicaltrialsonline.com | Don Tracy
Carvykti Delivers Long-Term Remission: One-third of patients in the CARTITUDE-1 trial achieved at least five years of treatment-free survival after a single CAR T-cell therapy infusion. Sustained Efficacy in High-Risk Patients: The trial included heavily pretreated and triple-class refractory populations, with median overall survival reaching over five years.
-
4 days ago |
appliedclinicaltrialsonline.com | Davy James
First Immunotherapy to Achieve Statistically Significant EFS in Resectable Gastric and GEJ Cancers. Imfinzi (durvalumab) combined with FLOT chemotherapy significantly improved event-free survival (EFS) versus chemotherapy alone in resectable Stage II–IVA gastric and gastroesophageal junction (GEJ) cancers, becoming the first immunotherapy to reach this milestone in a global Phase III trial. Durable Two-Year EFS and Strong Trend Toward OS Benefit.
-
5 days ago |
appliedclinicaltrialsonline.com | Davy James
First-Line Survival Milestone in BRAF V600E mCRCThe Braftovi (encorafenib) combination regimen is the first to show a statistically significant and clinically meaningful overall survival benefit in treatment-naïve patients with BRAF V600E-mutant metastatic colorectal cancer, doubling median OS to 30.3 months.
-
5 days ago |
appliedclinicaltrialsonline.com | Don Tracy |Andy Studna
June 3, 2025By In this video interview, Ron Lanton, partner, Lanton Law, highlights how tariffs on active pharmaceutical ingredients could affect resources for maintaining and accelerating R&D pipelines. In a recent video interview with Applied Clinical Trials, Ron Lanton, partner, Lanton Law, discussed the impact of drug cost increases on clinical research, predicting a reduction in government-sponsored trials due to higher R&D costs and potential funding cuts.
-
6 days ago |
appliedclinicaltrialsonline.com | Andy Studna
Key takeawaysEnhertu plus pertuzumab showed a 44% reduction in disease progression or death versus the current standard-of-care THP regimen. The combination therapy achieved a median PFS of 40.7 months, setting a new potential first-line standard for HER2-positive metastatic breast cancer. DESTINY-Breast09 highlights efficient trial execution across global sites, emphasizing the importance of well-structured multicenter design in oncology trials.
Applied Clinical Trials journalists
Contact details
Address
123 Example Street
City, Country 12345
Phone
+1 (555) 123-4567
Email Patterns
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →